Multinational pharmaceutical and laboratory apparatus provider, Sartorius, experienced a boom in both markets in 2022, and as a result has seen a significant rise in revenues.

Sartorius' most recent financial report has just been published, with figures boasting more than two times the increase in profit after taxes and minority interests.

“Sartorius, experienced a boom in both markets in 2022, and as a result has seen a significant rise in revenues“

This is tangibly represented by the 319 million euros generated in 2021, compared to the 678 million euros reported for the last fiscal year.

Using the basis of initial estimates, Sartorius had already released the majority of their critical numbers before the start of this month.

Revenue reported for 2022 showed an annual 20% increase, reaching a total of 4.2 billion euros.

The Executive Board has planned for a slower rate of growth in 2023 since the boost brought on by the Covid 19 pandemic is waning.

Investors are set to get a more substantial pay-out in 2022. If they are part of the DAX stock market, this will be 1.44 euros, and for common stock. 1.43 euros per share will be issued.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.